<p><em>The study estimated the safety of meloxicam in prolonged treatment of children with juvenile arthritis (JA). Clinical data and results of endoscopy of 50 patients with JA were analyzed. All patients were switched from diclofenac to meloxicam by different reasons. An estimation of hepatotoxicity of meloxicam compared to other non-steroidal anti-inflammatory drugs (NSAIDs) — diclofenac and nimesulid, was performed. The results of a study show that treatment with meloxicam decreases a risk of gastrointestinal adverse events in patients with JA. Hepatotoxicity rate of NSAIDs was 7,2%. Patients treated with meloxicam had lowest rate of transaminases increase.</em><strong><em></em></strong></p><p><strong><em>Key words: children, juvenile r...
<em>The study analyses efficiency and safety of using mono clone antibodies for tumor necrosis facto...
OBJECTIVE To analyse and report the incidence of side effects of biological agents in paediatric pa...
<em>The article presents the case report of a child with juvenile rheumatoid arthritis, systemic typ...
The use of NSAIDs for arthritis differs in children from adults in their indications, uses and pharm...
Meloxicam is a new preferential cyclooxygenase-2 (COX-2) inhibitor for the treatment of rheumatic di...
Meloxicam is a new non-steroidal anti-inflammatory drug (NSAID) which preferentially inhibits cycloo...
Contains fulltext : 195625.pdf (publisher's version ) (Open Access)OBJECTIVE: To e...
<em>The article presents the results of a study of effectiveness and safety of infliximab — monoclon...
To analyse and report the incidence of side effects of biological agents in paediatric patients with...
Meloxicam is a new non-steroidal anti-inflammatory drug (NSAID) which has potent anti-arthritic acti...
randomized, multicentre study in out-patients with symptomatic osteoarthritis (OA) of the hip. Asses...
Item does not contain fulltextOBJECTIVE: The current treatment options for systemic-onset juvenile i...
OBJECTIVE: To evaluate the safety of adalimumab in pediatric patients who participated in clinical t...
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) remain as the initial approach to the pha...
BACKGROUND: This study aimed to assess long-term safety and developmental data on juvenile idiopathi...
<em>The study analyses efficiency and safety of using mono clone antibodies for tumor necrosis facto...
OBJECTIVE To analyse and report the incidence of side effects of biological agents in paediatric pa...
<em>The article presents the case report of a child with juvenile rheumatoid arthritis, systemic typ...
The use of NSAIDs for arthritis differs in children from adults in their indications, uses and pharm...
Meloxicam is a new preferential cyclooxygenase-2 (COX-2) inhibitor for the treatment of rheumatic di...
Meloxicam is a new non-steroidal anti-inflammatory drug (NSAID) which preferentially inhibits cycloo...
Contains fulltext : 195625.pdf (publisher's version ) (Open Access)OBJECTIVE: To e...
<em>The article presents the results of a study of effectiveness and safety of infliximab — monoclon...
To analyse and report the incidence of side effects of biological agents in paediatric patients with...
Meloxicam is a new non-steroidal anti-inflammatory drug (NSAID) which has potent anti-arthritic acti...
randomized, multicentre study in out-patients with symptomatic osteoarthritis (OA) of the hip. Asses...
Item does not contain fulltextOBJECTIVE: The current treatment options for systemic-onset juvenile i...
OBJECTIVE: To evaluate the safety of adalimumab in pediatric patients who participated in clinical t...
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) remain as the initial approach to the pha...
BACKGROUND: This study aimed to assess long-term safety and developmental data on juvenile idiopathi...
<em>The study analyses efficiency and safety of using mono clone antibodies for tumor necrosis facto...
OBJECTIVE To analyse and report the incidence of side effects of biological agents in paediatric pa...
<em>The article presents the case report of a child with juvenile rheumatoid arthritis, systemic typ...